A faulty cancer gene helps tumors evade immunity by stopping tumor cells releasing message-containing cargoes called exosomes. These findings, published in eLife, provide what the editors say is fundamental insight into the underlying biology of hepato…
The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory chronic ly…
Fibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The disease is caused by a single genetic mutation that creates a fusion protein. Scientists at St. Jude Children’s Research Hospital and Th…
Most of the white blood cells in your body are a type of cell called neutrophils. Despite their high numbers, they are less well understood than other immune cells, in part because they have very short lifespans: an average neutrophil lives for only ei…
Monitoring levels of DNA shed by tumors and circulating in the bloodstream could help doctors accurately assess how gastroesophageal cancers are responding to treatment, and potentially predict future prognosis, suggests a new study led by researchers …
The MYCN oncoprotein (proteins related to the growth of cancer cells) plays a key role in starting, advancing and making it difficult to treat various human cancers. When MYCN is overactive, especially in high-risk neuroblastoma (childhood cancer often…
T cells are often called “assassins” or “killers” because they can orchestrate and carry out missions to hunt down bacteria, viruses, and cancer cells throughout the body. Mighty as they may be, recent research has shown that once T cells infiltrate th…
Scientists have developed an improved technique for reading the genetic material associated with the body’s immune response to cancer, making it possible to study tissue samples that have been stored in archives for decades.
A new strategy to fight an extremely aggressive type of brain tumor showed promise in a pair of experiments with a handful of patients.
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment. In a paper published in the New England Journal of Medicine,…
